← Eichor
Study identifier: NCT04057209 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

VoiceS: Voice Quality After Transoral CO2-Laser Surgery Versus Single Vocal Cord Irradiation for Larynx Cancer

Condition: Glottis Tumor · Larynx Cancer  ·  Sponsor: Olgun Elicin

PhaseNA
Planned participants34
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Laser surgery and radiotherapy are well-established standards of care for unilateral stage 0 \& I carcinoma in situ (Cais) and squamous cell carcinoma of glottic larynx (SCCGL). Based on meta-analyses, functional and oncological outcome after both treatment modalities are comparable1-5. However, no properly conducted randomized trials comparing these treatments exist. The only such trial with the endpoint of voice quality had to be prematurely closed due to low accrual6. The traditional radiotherapy involves the treatment of the whole larynx. Recently, a new radiotherapy technique was introduced by a team of researchers from Netherlands, where the treated target volume consists of involved vocal cord and therefore 8 to 10-fold smaller than the target volumes used for traditional whole larynx irradiation. The treatment is reduced to 16 fractions which corresponds to 3 weeks and a day7-12. The results of a prospective cohort (n=30) with single vocal cord irradiation (SVCI) were compared with the results of a historical prospective cohort previously treated with whole larynx radiotherapy (n=131) in the same institute. The median follow-up was 30 months. The voice handicap index (VHI) at all time points beginning from the 6th week after SVCI was significantly superior to the same time points with conventional radiotherapy. Moreover, a comparable local control with SVCI (100%) vs. conventional radiotherapy (92%) was reported at two years, p=0.2412. Based on this information, the…

This description comes directly from the study's public registry record.

Talk to the study team

Olgun Elicin, M.D.  ·  +41 31 632 26 32  ·  olgun.elicin@insel.ch

Timo Nannen  ·  +41 31 63 2 90 74  ·  timo.nannen@insel.ch

Always discuss trial participation with your own doctor first.

Locations (4)

Institut Gustave RoussyParis, FranceRecruiting
Tata Memorial Hospital MumbaiMumbai, Maharashtra, IndiaRecruiting
Inselspital, Bern University HospitalBern, Canton of Bern, SwitzerlandRecruiting
University Hospital ZurichZurich, Canton of Zurich, SwitzerlandRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04057209